androstenedione has been researched along with megestrol acetate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kollman, PA; Lee, DL; Marsh, FJ; Wolff, ME | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH | 1 |
| Albert, J; Geller, J; Kirshner, M; Liu, J | 1 |
| Frost, VJ; Helle, SI; Holly, JM; Lønning, PE; van der Stappen, JW | 1 |
| Bonnefoi, H; Castiglione, M; Cavalli, F; Fey, MF; Goldhirsch, A; Hsu-Schmitz, SF; Löhnert, T; Morant, R; Thürlimann, B | 1 |
| Rubens, RD | 1 |
| Helle, SI; Lonning, PE; Lundgren, S | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Bernhard, J; Bonnefoi, H; Castiglione-Gertsch, M; Cavalli, F; Fey, MF; Goldhirsch, A; Hürny, C; Morant, R; Schmitz, SF; Thürlimann, B | 2 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
1 review(s) available for androstenedione and megestrol acetate
| Article | Year |
|---|---|
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
6 trial(s) available for androstenedione and megestrol acetate
| Article | Year |
|---|---|
Adrenal steroids as parameters of the bioavailability of MA and MPA.
Topics: Adrenal Cortex Hormones; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; Hydrocortisone; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate | 1990 |
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Prospective Studies; Receptors, Estrogen; Regression Analysis; Remission Induction; Tamoxifen; Time Factors; Treatment Failure | 1997 |
Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Topics: Administration, Oral; Aged; Androstenedione; Appetite Stimulants; Area Under Curve; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Estrogens; Estrone; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Megestrol Acetate; Middle Aged; Postmenopause; Testosterone | 1996 |
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Megestrol Acetate; Middle Aged; Quality of Life; Tamoxifen; Treatment Failure | 1999 |
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Quality of Life; Statistics as Topic; Treatment Outcome | 1999 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
5 other study(ies) available for androstenedione and megestrol acetate
| Article | Year |
|---|---|
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
Topics: Androstenes; Animals; Guinea Pigs; Humans; Hydroxyprogesterones; Protein Binding; Rabbits; Receptors, Progesterone; Sheep; Steroids; Structure-Activity Relationship | 1977 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.
Topics: Adrenal Cortex; Aged; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Dihydrotestosterone; Epithelium; Humans; Hydrocortisone; Male; Megestrol; Megestrol Acetate; Middle Aged; Prostate; Prostatic Hyperplasia; Protein Biosynthesis; Testis; Testosterone | 1985 |
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Endopeptidases; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Megestrol Acetate; Middle Aged; Radioimmunoassay; Somatomedins | 1996 |
Aromatase inhibitors for breast cancer--further progress.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Megestrol Acetate | 1997 |